STOCK TITAN

ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage immuno-oncology company, announced its participation in the Cantor Oncology, Hematology & HemeOnc Conference on September 28, 2022, in New York. CEO Jaume Pons, Ph.D., will be part of a moderated panel titled “Building Combinations: What are the Novel Ideas?” at 10:40 AM ET. Additionally, Dr. Pons and CFO Peter Garcia will conduct one-on-one investor meetings during the event. ALX Oncology is advancing its lead product candidate, evorpacept, aimed at treating various cancers by blocking the CD47 checkpoint pathway.

Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer, will participate in a panel and investor meetings at the Cantor Oncology, Hematology & HemeOnc Conference on Wednesday, September 28 in New York.

Format: Moderated panel with analysts, Li Watsek & Brandon Folkes
Panel: “Building Combinations: What are the Novel Ideas?”
Date: Wednesday, September 28
Time: 10:40 AM Eastern Time
Location: New York, NY

Dr. Pons and Mr. Peter Garcia, CFO of ALX Oncology, will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with the ALX Oncology management team, please contact your Cantor conference representative.

About ALX Oncology

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies.


FAQ

What is the date of ALX Oncology's participation in the Cantor Conference?

ALX Oncology will participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28, 2022.

Who will represent ALX Oncology at the Cantor Conference?

CEO Jaume Pons and CFO Peter Garcia will represent ALX Oncology at the Cantor Conference.

What is the topic of the panel where ALX Oncology will participate?

The panel topic is “Building Combinations: What are the Novel Ideas?”

What time is ALX Oncology's panel discussion scheduled?

The panel discussion is scheduled for 10:40 AM Eastern Time.

How can one schedule a meeting with ALX Oncology management at the conference?

To schedule a meeting, attendees should contact their Cantor conference representative.

ALX Oncology Holdings Inc.

NASDAQ:ALXO

ALXO Rankings

ALXO Latest News

ALXO Stock Data

81.22M
41.97M
1.97%
88.23%
13.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO